Femasys (NASDAQ:FEMY) Given Buy Rating at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, Chardan Capital dropped their target price on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Performance

FEMY traded down $0.04 during trading on Tuesday, hitting $1.07. 80,115 shares of the company traded hands, compared to its average volume of 325,746. Femasys has a one year low of $0.73 and a one year high of $2.40. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The stock’s fifty day moving average is $1.14 and its 200 day moving average is $1.12. The firm has a market cap of $24.39 million, a P/E ratio of -1.31 and a beta of -2.89.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, equities analysts predict that Femasys will post -0.84 EPS for the current fiscal year.

Institutional Trading of Femasys

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Aljian Capital Management LLC bought a new stake in shares of Femasys in the 3rd quarter worth $27,000. XTX Topco Ltd increased its position in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after purchasing an additional 17,473 shares in the last quarter. Finally, CM Management LLC raised its stake in shares of Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after buying an additional 25,000 shares during the period. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.